The Translational Breast Cancer Research Consortium was well represented at the 2014 SABCS.  Presentations included:

Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC 003; Abstract #PD3-5

Whole transcriptome analysis of AR+ ER/PR- metastatic breast cancers treated with bicalutamide on TBCRC 011; Abstract #P3-04-01

TBCRC 023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endocrine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer; Abstract #S6-02

Characterization of male breast cancer: first results of the EORTC10085/ TBCRC/ BIG/ NABCG International Male BC Program (TBCRC 029); Abstract #S6-05